LSTA
Income statement / Annual
Last year (2024), Lisata Therapeutics, Inc.'s total revenue was $1.00 M,
and the percentage change from the previous year is not available.
In 2024, Lisata Therapeutics, Inc.'s net income was -$19.99 M.
See Lisata Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$35.28 M |
$22.49 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.00 K
|
$65.00 K
|
$225.00 K
|
$372.00 K
|
$450.27 K
|
$20.16 M
|
| Gross Profit |
$1.00 M
|
$0.00
|
$0.00
|
$0.00
|
-$63.00 K
|
-$65.00 K
|
-$225.00 K
|
-$372.00 K
|
$4.15 M
|
$2.33 M
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.12
|
0.1
|
| Research and Development Expenses |
$11.33 M
|
$12.73 M
|
$43.46 M
|
$17.58 M
|
$9.25 M
|
$13.50 M
|
$7.59 M
|
$17.14 M
|
$15.11 M
|
$23.90 M
|
| General & Administrative Expenses |
$12.08 M
|
$12.97 M
|
$14.14 M
|
$11.47 M
|
$9.89 M
|
$9.30 M
|
$9.39 M
|
$11.75 M
|
$12.80 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.08 M
|
$12.97 M
|
$14.14 M
|
$11.47 M
|
$9.89 M
|
$9.30 M
|
$9.39 M
|
$11.75 M
|
$12.80 M
|
$30.01 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.70 M
|
$824.00 K
|
-$1.30 M
|
$21.96 K
|
$0.00
|
| Operating Expenses |
$23.41 M
|
$25.71 M
|
$57.60 M
|
$29.05 M
|
$19.15 M
|
$20.09 M
|
$16.99 M
|
$27.59 M
|
$35.48 M
|
$53.91 M
|
| Cost And Expenses |
$23.41 M
|
$25.71 M
|
$57.60 M
|
$29.05 M
|
$19.15 M
|
$20.09 M
|
$16.99 M
|
$27.59 M
|
$29.50 M
|
$74.06 M
|
| Interest Income |
$1.88 M
|
$2.72 M
|
$1.05 M
|
$151.00 K
|
$132.00 K
|
$740.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.00 K
|
$377.77 K
|
$1.86 M
|
$2.13 M
|
| Depreciation & Amortization |
$174.00 K
|
$189.00 K
|
$69.00 K
|
$55.00 K
|
$63.00 K
|
$65.00 K
|
$225.00 K
|
$372.00 K
|
$450.27 K
|
$2.69 M
|
| EBITDA |
-$22.24 M |
-$25.52 M |
-$57.53 M |
-$29.00 M |
-$19.08 M |
-$20.03 M |
-$16.76 M |
-$27.22 M |
-$29.03 M |
-$93.44 M |
| EBITDA Ratio |
-22.24
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.82
|
-4.16
|
| Operating Income Ratio |
-22.41
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.89
|
-2.29
|
| Total Other Income/Expenses Net |
$1.63 M
|
$2.54 M
|
$897.00 K
|
$76.00 K
|
$132.00 K
|
$740.00 K
|
$819.00 K
|
-$105.00 K
|
-$1.76 M
|
-$46.68 M
|
| Income Before Tax |
-$20.78 M
|
-$23.17 M
|
-$56.70 M
|
-$28.97 M
|
-$19.01 M
|
-$19.35 M
|
-$16.17 M
|
-$27.70 M
|
-$31.26 M
|
-$98.25 M
|
| Income Before Tax Ratio |
-20.78
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.89
|
-4.37
|
| Income Tax Expense |
-$798.00 K
|
-$2.33 M
|
-$2.48 M
|
-$1.51 M
|
-$10.87 M
|
$0.00
|
-$1.00 K
|
-$11.53 M
|
$138.04 K
|
-$17.24 M
|
| Net Income |
-$19.99 M
|
-$20.84 M
|
-$54.23 M
|
-$27.47 M
|
-$8.15 M
|
-$20.10 M
|
-$16.17 M
|
$22.98 M
|
-$32.66 M
|
-$80.89 M
|
| Net Income Ratio |
-19.99
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.93
|
-3.6
|
| EPS |
-2.4 |
-2.58 |
-10.47 |
-7.45 |
-7.91 |
-29.2 |
-25.03 |
38.43 |
-74.81 |
-250.12 |
| EPS Diluted |
-2.4 |
-2.58 |
-10.47 |
-7.45 |
-7.91 |
-29.2 |
-25.03 |
38.43 |
-74.81 |
-250.12 |
| Weighted Average Shares Out |
$8.33 M
|
$8.07 M
|
$5.18 M
|
$3.69 M
|
$1.03 M
|
$688.33 K
|
$645.93 K
|
$633.87 K
|
$436.55 K
|
$323.39 K
|
| Weighted Average Shares Out Diluted |
$8.33 M
|
$8.07 M
|
$5.18 M
|
$3.69 M
|
$1.03 M
|
$688.33 K
|
$645.93 K
|
$597.93 K
|
$436.55 K
|
$323.39 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
